Corteva (CTVA) surged 12% following a JPMorgan upgrade to Overweight with a $19 price target, implying 37% upside. The rally was fueled by the company's separation from Vylor and its inclusion in the S&P MidCap 400. Trading at 5.7x 2027 EBITDA, Corteva is positioned as a deep-value opportunity in crop protection, though legal liabilities from PFAS/PFOA concerns remain a risk factor.
Axe note: JPMorgan’s bullish call on Corteva highlights deep value after its spin-off, though legal liabilities temper enthusiasm.